SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence